Trials / Completed
CompletedNCT03006445
Study of FYU-981 in Hyperuricemia With or Without Gout
Official Title: Safety and Efficacy Evaluation Study of FYU-981 Long-term Administration for Hyperuricemia With or Without Gout (Phase III Study)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (actual)
- Sponsor
- Fuji Yakuhin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is confirmatory investigation of safety and efficacy of FYU-981 administered orally to hyperuricemic patients with and without gout for 34 or 58 weeks by the method of multicenter, open label and ascending dose regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FYU-981 |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2018-08-23
- Completion
- 2018-10-24
- First posted
- 2016-12-30
- Last updated
- 2018-12-06
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03006445. Inclusion in this directory is not an endorsement.